[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 75 of about 75
1. Wang C, Xu YQ: Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative? Gastroenterology Res; 2008 Dec;1(1):2-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative?
  • : Diphenyl dimethyl bicarboxylate (DDB) has been used in some countries as hepatoprotectant adjuvant in the treatment of liver diseases, such as chronic viral hepatitis, chemical or drug induced hepatic damage.
  • Its early confirmed efficacy is to normalize elevated blood alanine aminotransferase (ALT) from different etiologies, however, it can rarely affect the rest hepatic enzymes.
  • In addition, the lowering or normalization of ALT in most cases occurs during DDB treatment, withdrawal of DDB administration results in ALT re-elevated.
  • Hence, for a long time, it has been only used as adjuvant of liver disease therapy.
  • The normalization of ALT in hepatitis does not indicate therapeutic efficacy if without substantial liver histology improvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994699.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; adjuvant / dimethyl diphenyl bicarboxylate / liver disease / schisandra chinensis / schisandrin B / viral hepatitis
  •  go-up   go-down


2. Hamano A, Yamashita Y, Katoh Y, Yumura Y, Mikata K, Takase K, Ohgo Y, Noguchi S, Nagashima Y: [Two cases of retroperitoneal liposarcoma arisen from perirenal fat tissue, which could not be diagnosed preoperatively]. Hinyokika Kiyo; 2004 Dec;50(12):857-60
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of retroperitoneal liposarcoma arisen from perirenal fat tissue, which could not be diagnosed preoperatively].
  • We report two cases of retroperitoneal liposarcoma arisen from the perirenal fat tissue, which could not be diagnosed preoperatively.
  • He complained of left flank tumor.
  • Computed tomography and magnetic resonance image showed a mass over 10 cm that contained fat components in the retroperitoneal space.
  • The tumor was resected with left nephrectomy and histological examination revealed well differentiated liposarcoma.
  • As adjuvant therapy, he received chemotherapy and 30 months has passed uneventfully.
  • Screening ultrasonography revealed incidental retroperitoneal tumor.
  • With clinical diagnosis as non-functioning adrenal tumor, he received left nephrectomy.
  • The pathological diagnosis was well differentiated liposarcoma, sclerosing type.
  • No adjuvant therapy was performed.
  • The characteristics of the images of the two cases were different despite the histological resemblance.
  • This difference was considered to be due to the difference in the distribution of lipomatous tissue in each patient.
  • [MeSH-major] Adipose Tissue / pathology. Kidney / pathology. Liposarcoma / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Drug Administration Schedule. Epirubicin / administration & dosage. Humans. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682857.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; MEC protocol 2
  •  go-up   go-down


3. Anand Rajan KD, Subbarao KC, Agarwala S, Gupta SD: Mediastinal liposarcoma of mixed type in childhood: a report of a case with unusual histologic features. Indian J Pathol Microbiol; 2010 Jul-Sep;53(3):525-8
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal liposarcoma of mixed type in childhood: a report of a case with unusual histologic features.
  • We hereby report the occurrence of mediastinal liposarcoma in a 11-year-old female child.
  • Dyspnea and wheezing of long-standing duration were the presenting complaints and a preoperative biopsy failed to yield the diagnosis.
  • Histologic examination revealed heterogeneous areas with well-differentiated liposarcoma-like areas, areas resembling myxoid liposarcoma, and areas of dedifferentiation.
  • Liposarcomas in the mediastinum are extremely rare tumors of childhood and the present case showed unusual histologic features.
  • Complete surgical excision with clear surgical margins remains the primary modality of treatment, although chemotherapy and radiotherapy have been tried.
  • [MeSH-major] Liposarcoma / diagnosis. Liposarcoma / pathology. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Child. Dyspnea / etiology. Female. Histocytochemistry. Humans. Microscopy. Radiography, Thoracic. Respiratory Sounds / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20699516.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O: Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene; 2002 Mar 28;21(14):2261-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gains of 1q21-q23 have been associated with metastasis and chemotherapy response, particularly in bladder cancer, hepatocellular carcinomas and sarcomas.
  • COAS2 was overexpressed almost exclusively in aggressive metastatic or chemotherapy resistant tumours.
  • Although COAS2 was generally more amplified than COAS1, it was not expressed in well-differentiated liposarcomas, where amplification of this region is very common.
  • Quite likely, the different genes may give selective advantages to different subsets of tumours.
  • [MeSH-minor] Amino Acid Sequence. Cloning, Molecular. Gene Expression Profiling. Humans. In Situ Hybridization, Fluorescence. Molecular Sequence Data. Organ Specificity. Physical Chromosome Mapping. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Sequence Homology, Amino Acid. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11948409.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB033071/ AF345651/ AL117237/ BG154169
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm; EC 5.2.1.- / Cyclophilins
  •  go-up   go-down


5. Benaragama KS, Neequaye SK, Maudgil D, Gordon AG: Small bowel liposarcoma--a rare cause of small bowel perforation. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel liposarcoma--a rare cause of small bowel perforation.
  • The histology demonstrated a well-differentiated liposarcoma.
  • Liposarcomas are the most common soft tissue sarcomas in adults but occurrence in the gastrointestinal tract is extremely rare.
  • Surgical resection with clear margins is the treatment of choice for primary liposarcomas.
  • They are moderately radiosensitive and chemotherapy is non-effective.
  • Although gastrointestinal liposarcomas have been previously reported, this is the first reported case of a primary liposarcoma associated with a small bowel perforation.
  • [MeSH-major] Ileal Neoplasms / diagnosis. Intestinal Perforation / etiology. Liposarcoma / diagnosis
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Ileal Diseases / diagnosis. Ileal Diseases / etiology. Male

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1972 Aug;58(2):172-6 [5056514.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1975;(253):1-71 [1059326.001]
  • [Cites] Am J Gastroenterol. 1988 Jan;83(1):89-92 [3337069.001]
  • [Cites] Tumori. 1993 Apr 30;79(2):77-91 [8346570.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jan;164(1):129-34 [7998525.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):389-94 [10379861.001]
  • [Cites] Int Surg. 1999 Apr-Jun;84(2):163-7 [10408290.001]
  • (PMID = 22791735.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029041
  •  go-up   go-down


6. Dubin MR, Chang EW: Liposarcoma of the tongue: case report and review of the literature. Head Face Med; 2006;2:21
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the tongue: case report and review of the literature.
  • BACKGROUND: Liposarcoma most commonly arises in the retroperitoneum and lower extremities.
  • Liposarcoma of the head and neck is rare, with only 12 previously reported cases of liposarcoma in the tongue.
  • CASE PRESENTATION: We present a case of well-differentiated liposarcoma of the tongue occurring in a 39 year old man, treated with surgical excision.
  • CONCLUSION: Liposarcoma of the head and neck is rare, and may easily be misdiagnosed clinically.
  • The diagnosis is made histologically.
  • Wide surgical excision is the treatment of choice, with limited data to support the use of radiation or chemotherapy.
  • Our case represents the longest follow-up period for a tongue liposarcoma, with 14 years disease-free following surgical extirpation.
  • [MeSH-major] Liposarcoma / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Jan;89(1):66-72 [10630944.001]
  • [Cites] Oral Dis. 2004 Nov;10(6):398-400 [15533218.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Aug;92(2):194-201 [11505267.001]
  • [Cites] J Laryngol Otol. 2001 Oct;115(10):859-61 [11668010.001]
  • [Cites] Acta Otolaryngol. 2001 Sep;121(6):759-62 [11678177.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):117-9 [11755832.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1020-31 [12379747.001]
  • [Cites] J Otolaryngol. 2002 Oct;31(5):327-8 [12512900.001]
  • [Cites] Am J Otolaryngol. 2003 Mar-Apr;24(2):121-7 [12649828.001]
  • [Cites] J Otolaryngol. 1976 Oct;5(5):410-4 [994279.001]
  • [Cites] Cancer. 1979 Feb;43(2):574-84 [421182.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):507-23 [534388.001]
  • [Cites] J Am Dent Assoc. 1984 Feb;108(2):231-2 [6584498.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Mar;63(3):348-50 [3473362.001]
  • [Cites] Br J Oral Maxillofac Surg. 1992 Aug;30(4):268-9 [1510904.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Oct;118(10):1045-9 [1389054.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jun;52(6):595-8 [8189297.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Oct;120(10):1151-5 [7917199.001]
  • [Cites] J Oral Pathol Med. 1995 Apr;24(4):180-4 [7783007.001]
  • [Cites] Arch Pathol Lab Med. 1996 Mar;120(3):292-5 [8629909.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1051-8 [8625207.001]
  • [Cites] J Oral Maxillofac Surg. 1998 Feb;56(2):224-7 [9461149.001]
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):452-6 [10349380.001]
  • [Cites] Surgery. 1954 Oct;36(4):687-712 [13195985.001]
  • [Cites] Cancer. 1960 Sep-Oct;13:932-50 [13696965.001]
  • [Cites] Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:367-88 [13890373.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2000 Jul;109(7):683-6 [10903052.001]
  • (PMID = 16872488.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC1553437
  • [General-notes] NLM/ Original DateCompleted: 20070720
  •  go-up   go-down


7. Chen JH, Enloe BM, Weybright P, Campbell N, Dorfman D, Fletcher CD, Cory DG, Singer S: Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. Magn Reson Med; 2002 Oct;48(4):602-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thiazolidinediones, a class of synthetic ligands to the peroxisome proliferator-activated receptor-gamma, induce terminal adipocyte differentiation of 3T3 F442A cells, and have already been used as alternative therapeutic agents for the treatment of liposarcoma in clinical trials.
  • The biochemical changes occurring in the 3T3 F442A cell line and well-differentiated liposarcoma following induction of adipocyte differentiation with the thiazolidinedione troglitazone were measured using high-resolution magic angle spinning (MAS) nuclear magnetic resonance (NMR) spectroscopy.
  • The molar ratio of PTC to PC increased fourfold in differentiated 3T3 F442A cells compared to undifferentiated cells, suggesting a substantial increase in CTP:phosphocholine cytidylyltransferase activity with differentiation.
  • A 2.8-fold increase in the PTC:PC ratio was observed in the lipoma-like well-differentiated liposarcoma of three patients who were treated with troglitazone when compared to liposarcoma from patients not treated with this drug.
  • Thus, this ratio may be an NMR-detectable marker of troglitazone efficacy and response to differentiation therapy for liposarcoma.
  • [MeSH-major] Adipocytes / metabolism. Cell Differentiation / drug effects. Magnetic Resonance Spectroscopy / methods. Thiazoles / pharmacology. Thiazolidinediones
  • [MeSH-minor] 3T3 Cells. Animals. Antineoplastic Agents / therapeutic use. Cells, Cultured. Chromans / therapeutic use. Flow Cytometry. Humans. Ligands. Liposarcoma / drug therapy. Liposarcoma / metabolism. Mice. Phosphatidylcholines / metabolism. Phosphorylcholine / metabolism. Receptors, Cytoplasmic and Nuclear / metabolism. Transcription Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12353276.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA75720; United States / NCI NIH HHS / CA / R21-CA83759
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromans; 0 / Ligands; 0 / Phosphatidylcholines; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Thiazoles; 0 / Thiazolidinediones; 0 / Transcription Factors; 107-73-3 / Phosphorylcholine; 2295-31-0 / 2,4-thiazolidinedione; I66ZZ0ZN0E / troglitazone
  •  go-up   go-down


8. Gupta R, Sharma A, Arora R, Kulkarni MP, Chattopadhaya TK, Singh MK: Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist. J Gastrointest Cancer; 2010 Mar;41(1):79-83
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist.
  • BACKGROUND: Mesenteric liposarcoma is a rare intra-abdominal sarcoma with very few cases reported in the available English literature.
  • Incomplete resection of the tumor leads to recurrence, and recurrent tumors carry a risk of dedifferentiation.
  • Dedifferentiation in liposarcoma manifests as a nonlipogenic sarcoma, which is usually high-grade and may show osteosarcomatous differentiation rarely.
  • To the best of our knowledge, osteoid metaplasia in a well-differentiated liposarcoma without evidence of dedifferentiation has not been documented in the available literature.
  • CASE: We describe the case of a middle-aged adult man with a well-differentiated liposarcoma of the mesentery.
  • The patient presented with a recurrent tumor 5 years after the initial surgery.
  • At recurrence, the histological features were those of a well-differentiated liposarcoma with focal osseous metaplasia without any evidence of dedifferentiation in the extensive sections examined.
  • CONCLUSION: Osseous metaplasia is a rare phenomenon in lipomas and dedifferentiated liposarcomas.
  • Such an occurrence in a recurrent well-differentiated liposarcoma is a perplexing problem due to the potential confusion with dedifferentiation.
  • This needs to be recognized to avoid overzealous chemotherapy and/or radiotherapy, which is required for dedifferentiated tumors.
  • [MeSH-major] Calcinosis / pathology. Liposarcoma / pathology. Mesentery / pathology. Neoplasm Recurrence, Local / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Metaplasia. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med. 2007;46(7):373-5 [17409600.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1150-7 [7943536.001]
  • [Cites] World J Gastroenterol. 2007 Aug 14;13(30):4147-8 [17696239.001]
  • [Cites] Skeletal Radiol. 2003 May;32(5):286-9 [12679843.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):669-75 [16003776.001]
  • [Cites] Clin Neuropathol. 1996 Jan-Feb;15(1):60-2 [8998859.001]
  • [Cites] Jpn J Clin Oncol. 2006 Nov;36(11):735-8 [17000700.001]
  • [Cites] Semin Diagn Pathol. 2001 Nov;18(4):258-62 [11757865.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):829-33 [8610559.001]
  • [Cites] Intern Med. 1998 Oct;37(10):884-90 [9840715.001]
  • [Cites] Surg Today. 1994;24(11):1003-6 [7772897.001]
  • (PMID = 20058101.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Ylagan LR, Bhalla S: Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up. Acta Cytol; 2001 Jul-Aug;45(4):641-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up.
  • BACKGROUND: Dedifferentiation is a histologic progression of a neoplasm from low grade to high grade histology.
  • It occurs in tumors of the retroperitoneum and in those undergoing treatment.
  • This usually occurs in the setting of radiation or chemotherapy or as a spontaneous process over a long period.
  • CASE: We report the cytologic features of a dedifferentiated liposarcoma arising in a 76-year-old man who had a history of well-differentiated liposarcoma.
  • There were multinucleated, pleomorphic giant cells with abundant cytoplasm, smaller clusters of cells with a high nuclear/cytoplasmic ratio and cells with spindled and elongated nuclear features.
  • The follow-up surgical resection specimen showed a dedifferentiated liposarcoma with strong and diffuse immunoreactivity to vimentin, desmin and CD68 in the large, pleomorphic cells; focal and weak immunoreactivity to smooth muscle actin and S-100 in these cells; and strong and focal immunoreactivity to desmin, smooth muscle actin and muscle-specific actin in the spindle cells.
  • This supports the dedifferentiated components of this tumor to be of fibrohistiocytic and leiomyosarcomatous differentiation.
  • CONCLUSION: Dedifferentiation of a well-differentiated liposarcoma should be entertained in the setting of a mass lesion in the retroperitoneum in patients with prior histories of well-differentiated liposarcoma.
  • The radiologic features of a particular neoplastic process can be very helpful in determining the nature of this process.
  • [MeSH-major] Biopsy, Needle. Liposarcoma / pathology. Pelvic Neoplasms / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Male. Pelvis / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11480734.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Yokoi M, Hosokawa K, Funaki H, Yoshitani S, Kinami S, Omote K, Ueda N, Nakano Y, Kosaka T, Minato H: [A case of retroperitoneal dedifferentiated liposarcoma successfully treated with IFM and CDDP]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2114-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal dedifferentiated liposarcoma successfully treated with IFM and CDDP].
  • The patient was diagnosed with retroperitoneal liposarcoma.
  • Surgery was performed including the tumor, small bowel, and sigmoid resection, and an artificial anus was constructed.
  • On histopathology, the dark red lesions showed dedifferentiated liposarcoma, and the yellowish lesions showed well-differentiated liposarcoma.
  • Despite VAC chemotherapy (VCR 1.5 mg, ACD 0.5 mg, CPA 900 mg), progressive disease (PD) was noted.
  • As second-line chemotherapy, weekly IFM (2 g)+CDDP (30 mg) was given.
  • Shrinkage of the tumor infiltrates in the artificial anus, decreased abdominal bloating, and improved QOL were observed.
  • This case suggests that IFM+CDDP may be useful in dedifferentiated liposarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liposarcoma / drug therapy. Retroperitoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037341.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


11. Kostka R, Baitler T, Zachoval R, Sosna B, Palascak P: [Liposarcoma of the spermatic cord]. Prog Urol; 2006 Apr;16(2):215-7
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma of the spermatic cord].
  • Liposarcoma of the spermatic cord is rare.
  • It usually presents as a painless slowly-growing scrotal mass of consistency like lipoma.
  • Value of adjuvant radiotherapy/chemotherapy remains uncertain.
  • Recurrences are frequent, owing to incomplete surgical removal of the tumor.
  • We report on a 62 year old male who presented with a half a year history of a soft painless mass in the left scrotum extending from the groin up to the testis.
  • Histological examination revealed a well-differentiated liposarcoma of sclerosing subtype.
  • No evidence of recurrence or metastases has been noted during the 6-month and one year follow-up without any postoperative adjuvant therapy.
  • [MeSH-major] Genital Neoplasms, Male. Liposarcoma. Spermatic Cord

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734250.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Yamamoto T, Marui T, Akisue T, Hitora T, Kawamoto T, Nagira K, Nakatani T, Yoshiya S, Kurosaka M: Management of liposarcoma occurring in pregnant women. Anticancer Res; 2003 Jan-Feb;23(1B):799-802
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of liposarcoma occurring in pregnant women.
  • BACKGROUND: The coexistence of pregnancy and liposarcoma is rare.
  • Only 12 cases of pregnancy-associated liposarcoma have previously been reported in the English-language literature.
  • MATERIALS AND METHODS: We present two cases of liposarcoma occurring in pregnant patients: one myxoid liposarcoma in a 29-year-old woman at 29 weeks' gestation; another well-differentiated liposarcoma in a 44-year-old woman at 22 weeks' gestation.
  • The patient was subsequently treated with chemotherapy and radiotherapy.
  • The second patient awaited delivery until 32 weeks' gestation with no treatment of the tumor because she had a low-grade sarcoma.
  • After cesarean section, surgical treatment followed.
  • CONCLUSION: Treatment of sarcomas occurring during pregnancy is difficult.
  • Both mother and fetus should be appropriately managed, depending on the trimester at the time of diagnosis and the histological type and grade of the tumor.
  • [MeSH-major] Liposarcoma / therapy. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Cesarean Section. Combined Modality Therapy. Extremities. Female. Humans. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12680186.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Dennis PA, Blumenthal G, Ballas M, Gardner E, Kawabata S, LoPiccolo J, Helsabeck C, Root H, Figg WD, Bernstein W: A phase I study of nelfinavir, an FDA approved HIV protease inhibitor, in adults with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts were treated on a modified Fibonacci dose-escalation scheme with a twice daily oral dose of N starting at the FDA approved dose of 1250 mg bid on a 21-day cycle.
  • Therapy continued until MTD or disease progression.
  • PBMCs as well as optional tumor biopsies were collected for Akt inhibition and expression of markers of ER stress (ERS).
  • Tumor types included NSCLC (3), SCLC (2), thyroid (3), pancreatic (1), colorectal (1), and renal cell (1).
  • Median number of prior systemic therapies was 2 (range, 1 - 6).
  • There was no relationship between the drug levels and albumin levels.
  • CONCLUSIONS: N appears to be well tolerated in subjects with advanced solid tumors at 2.5 times the FDA approved dose.
  • AUC data suggest that there may be only minimal increases in plasma drug concentrations with doses above 1875 mg twice daily.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961900.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Gomez HL, Philco M, Castaneda C, Pimentel P, Escandon R, Seroogy J, Saikali K, Wolff A, Conlan M: A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence. J Clin Oncol; 2009 May 20;27(15_suppl):1077

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence.
  • Eligibility criteria: advanced breast cancer; no prior chemotherapy (CT) except neoadjuvant or adjuvant and ≥ 1 yr elapsed since CT; no CNS metastases; ECOG 0-1.
  • CONCLUSIONS: Ispinesib appears to be well tolerated on a q14d dosing schedule at doses tested to date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Taylor SK, Chia S, Dent S, Clemons M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard K, Leighl N: A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol; 2009 May 20;27(15_suppl):1133

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 1133 Background: Pazopanib, an oral small molecule inhibitor of VEGFR, PDGFR, and KIT, has demonstrated activity in phase I, with a recommended phase II dose of 800 mg/d (Hurwitz H et al, J Clin Oncol.
  • Treatment was continued until progression.
  • Prior lines of chemotherapy were 1 in 76% and 2 in 14%.
  • Of the 19 evaluable patients, 2 patients remain on treatment.
  • Median time to progression (TTP) was 3.7 months (95% C.I.
  • CONCLUSIONS: Pazopanib is well tolerated and demonstrates activity in pretreated breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962243.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Prados M, Yung W, Wen P, Junck L, Fink K, Cloughesy T, Robins I, Chang S, Kuhn J: Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. J Clin Oncol; 2004 Jul 15;22(14_suppl):1504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium.
  • : 1504 Background: To define the MTD of ZD1839 in combination with Temodar in patients with malignant glioma, without (Group A) or with (Group B) enzyme-inducing antiepileptic drugs (EIAEDs).
  • No more than 3 prior chemotherapy regimens allowed.
  • TREATMENT: Patients started on a continuous dose of ZD1839 (day 1) beginning at 500 mg/day.
  • DLT was defined as any grade 3 or greater non-hematological or any grade 4 hematological toxicity using CTC v 2.0 during the first 35 days of therapy.
  • Patients could continue treatment indefinitely until tumor progression or unacceptable toxicity.
  • DLT's at 500 mg were grade 3 diarrhea and ALT elevations.
  • DLT's at 1250 mg included grade 3 diarrhea, vomiting, hyponatremia and weakness, and grade 4 hypokalemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015386.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Muzikansky A, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Sahani DV: Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). J Clin Oncol; 2009 May 20;27(15_suppl):4578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX).
  • We also assessed the use of FDG-PET as an early indicator of response following treatment.
  • METHODS: Eligibility criteria included unresectable or metastatic measurable BTCs, 0-1 prior chemotherapy regimens, performance status ≤ 2, and adequate organ functions.
  • Pts were treated with all 3 drugs intravenously on days 1 and 15 every 28 days (one cycle): B was given first at 10 mg/kg, followed by GEM at 1000 mg/m<sup>2</sup> as a dose-rate infusion at 10 mg/m<sup>2</sup>/minute, and OX at 85 mg/m<sup>2</sup>.
  • Treatment related grade 3-4 toxicities included neutropenia (20%), ALT (17%), neuropathy (14%), hypertension (11%), AST (9%), anorexia (9%), and thrombocytopenia (9%).
  • With a median follow up of 9.9 months, the median overall survival was 13.2 months (95% CI, 7.3 to 20.5 months), and the median PFS was 7.0 months (95% CI, 5.4 to 9.6 months).
  • The mean baseline SUVmax was 5.72±2.01 and post-treatment SUVmax was 3.73±1.88 with a median 36.4% decrease (n=32).
  • An increase in adjusted post- to pre-treatment SUV increased the risk for tumor progression (hazard ratio=3.054).
  • FDG-PET showed significant early decreases in SUVmax following treatment, and these changes correlated with tumor response and time to tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963071.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Drullinsky P, Fornier MN, Sugarman S, D'Andrea G, Troso-Sandoval T, Seidman AD, Yuan J, Patil S, Norton L, Hudis C: Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):590

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 590 Background: CMF (C 600 mg/m<sup>2</sup>, M 40 mg/m<sup>2</sup>, F 600 mg/m<sup>2</sup>) is an option for adjuvant therapy for patients with low risk early stage breast cancer.
  • DD regimens as predicted by mathematical models of cancer growth and treatment response are superior.
  • METHODS: An initial cohort (A) was treated q 14 d with PEG-filgrastim (Neulasta) support.
  • A second cohort (B) was treated every 10-11 d with filgrastim/Neupogen x 5 d and then, based on feasibility, modified (cohort C) to use 7 d filgrastim.
  • The primary end point was feasibility defined as having ANC > 1.5 x 10<sup>3</sup>/uL on day 1 of planned treatment for all 8 cycles with no grade 3 or higher non-hematologic toxicity.
  • All three cohorts were tested using a Simon's two-stage optimal design with type I and type II errors set at 10%.
  • 6 out of 7 pts could not complete 8 cycles of chemotherapy secondary to neutropenia and 1 secondary to grade 3 ALT elevation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960702.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Erlichman C, Toft D, Reid J, Goetz M, Ames M, Mandrekar S, Ajei A, McCollum A, Ivy P: A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):3030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3030 Background: Therapy directed at the molecular chaperone HSP90 causes degradation of multiple client proteins critical in cancer cell proliferation and survival.
  • METHODS: We performed a phase I trial to determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of 17AAG infused on days 1, 4, 8 and 11 of a 21 day cycle, to characterize the pharmacokinetics of 17AAG and its effect on chaperone and client proteins in peripheral blood mononuclear cells (PBMCs).
  • Both patients treated at 308 mg/m<sup>2</sup> experienced one or more of the non-hematologic DLTs: hyperglycemia, dehydration, diarrhea (with maximal supportive treatment), ALT, AST, and alkaline phosphatase.
  • No tumor responses were seen, but one patient with metastatic melanoma was stable for ∼ 6 months on this treatment.
  • 17AAG consistently increased HSP70 and HSF-1 in PBMCs 6 and 25 hours after treatment over pretreatment levels (p < 0.01).
  • A newly identified client protein, Integrin-linked Kinase (ILK) was decreased significantly (p < 0.01) at 6 hours but not 25 hours after start of treatment on day 1 when compared to pretreatment levels.
  • These results indicate that 17AAG is tolerable on a twice-weekly schedule and that at the MTD the drug affects the target in normal tissue.
  • Patients are being accrued to assess the effects on tumor tissue. (Supported in part by CA15083, CA69912, CA90390, and M01-RR00585) [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Nisticò C, Bria E, Carpino A, Vitelli G, Cuppone F, Izzo F, Tropea F, Vanni B, Astorre P, Terzoli E: Evaluation of weekly epirubicin-paclitaxel (EP) cardiotoxicity with serum troponin-t and myoglobin and echocardiography in advanced breast cancer (ABC). J Clin Oncol; 2004 Jul 15;22(14_suppl):775

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • E/A ratio is useful to assay diastolic function to predict systolic failure.
  • CONCLUSIONS: No TnT/M and L-FEV/E/A alteration were seen in our subset of ABC non-symptomatic pts during weekly chemotherapy with E and P.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014205.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14527 Background: Preclinical studies demonstrate synergistic anti-tumor activity with the combination of E + C.
  • METHODS: Patients received E per oral for days 1-21 of a 28 day cycle.
  • RESULTS: 24 patients enrolled: 13 M, 11F; median age 62 (32-77); median number of prior cytotoxic chemotherapy regimens 1 (0-3; 75% with prior RT).
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME, Tan W, Iyer R, Yang G, Pendyala L: Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP). J Clin Oncol; 2009 May 20;27(15_suppl):e15543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15543 Background: Novel chemotherapy regimens in combination with RT aim to improve the pathologic complete response (pCR) in EC.
  • Following our dose-finding phase I study, the present phase II neo-adjuvant (NA) EC trial was designed to examine the pCR rate using C, OXP and RT, with secondary end-points of evaluating toxicity, quality of life, and GEP of tumor tissue for correlation to therapeutic response.
  • Treatment consisted of OXP, 85mg/m<sup>2</sup> iv on days 1, 15 and 29, C (oral or enteral tube) 625 mg/m<sup>2</sup> bid on days of RT, and 50.4 Gy RT (3-D conformal) in 28 fractions, followed by an esophagectomy (E) 4-6 weeks later.
  • GEP using Agilent microarrays was conducted on primary tumor tissue pre-treatment (Rx), day (D) 17 and at E; > 50% viable tumor cells were required.
  • 18 PTS have completed NA therapy; Grade 4 toxicity includes anemia (1), lymphopenia (2); grade 3 toxicity includes esophagitis (1), pneumonia (1), wound infection (1), anastomotic leak (2), esophageal fistula (1), bowel obstruction (1), fatigue (1), hyperbilirubinemia (1), elevated ALT, AST (1 & 2, respectively), hypoalbuminemia (3), OXP hypersensitivity (2) & leucopenia (1).
  • The exploratory GEP analysis may provide insight on predicting response to NA therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962302.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Cioffi A, LeCesne A, Blay J, Delaloge S, Yovine A, Maki R, Nieto A, Jiao JJ, Demetri GD: Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its unique antitumor properties, attributed to specific binding to the small groove of DNA, have been demonstrated activity against soft-tissue sarcoma (STS), ovarian, breast and prostate cancer.
  • Trabectedin treatment has been authorized by EMEA for STS after failure of standard treatment and shows efficacy in relapsed ovarian cancer in a phase III study.
  • MedDRA and NCI-CTC v1.0/2.0 were used to code and grade treatment-emergent adverse events (AEs).
  • Diagnosis included sarcoma (56%), ovary (26%) and breast (7%) cancer, for which 90% of pts had received chemotherapy, 37.5% radiotherapy, and 96.0% surgery.
  • Trabectedin lasted for a median of 3 cy (9.4 wks) and 28% of pts received ≥ 6 cycles, with a median dose intensity of 0.4 (0.1-0.6) mg/m<sup>2</sup>/wk.
  • Fifteen drug-related deaths (1.3%) occurred.
  • CONCLUSIONS: Single-agent trabectedin was reasonably well tolerated, with low rates of drug-related discontinuations and deaths.
  • Sustained clinical benefit in the absence of relevant cumulative toxicities allows its administration to patients for prolonged periods of time.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Sezgin VC, Sanli UA, Karabulut B, Uslu R, Muezzinoglu GG, Ozdemir N, Goker E: Capecitabine (X) monotherapy in patients (pts) with pretreated metastatic breast cancer (MBC): Is response correlated to cerbB-2 expression? J Clin Oncol; 2004 Jul 15;22(14_suppl):760

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 760 Background: Most chemotherapy regimens have marginal activity in pts with heavily pretreated MBC, with the exception of X, which consistently results in overall response rates (ORR) of approximately 20% and overall survival of around 1 year.
  • We studied the efficacy and safety of X in heavily pretreated pts with MBC, with a view to identifying potential predictors of progression-free survival (PFS).
  • RESULTS: 56/58 pts had prior anthracyclines and taxanes either as adjuvant or MBC therapy, 3% had cardiac contraindication to anthracyclines, 72% had ≥3 prior regimens, 50% had >1 metastatic site, 45% were ER/PR positive, and 60% were cerbB-2 positive (includes +1, +2, +3).
  • The ORR was 17% with a median duration of 9.4 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014156.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Yeatman T, Rocha Lima CM, Barthel J, Calvin D, Garret C, Dinwoodie WR, Mayfield S, Wright M, Lush R, Sullivan D: Phase I trial of oral topotecan (OT) and radiotherapy (XRT) in rectal cancer (RCA). J Clin Oncol; 2004 Jul 15;22(14_suppl):3743

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: To define the MTD, DLT, and PKs (blood samples at time 0 - immediately after taking OT - and at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, and 8 hrs after).
  • OT escalated in cohorts of 3 to 6 pts taken at least 3 hrs prior to 1.8 Gy/fraction XRT to a total of 45Gy (standard pelvic fields), Monday through Friday.
  • 5-FU-based chemotherapy in the adjuvant setting was offered off protocol.
  • CONCLUSION: This preoperative OT/XRT regimen has been well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014109.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Traina TA, Theodoulou M, Feigin K, Patil S, Geneus S, Modi S, Fornier M, Lake D, Norton L, Hudis C: Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab. J Clin Oncol; 2009 May 20;27(15_suppl):1131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab.
  • Lapatinib (L) improves time to progression when added to C(14 - 7) in patients (pts) with HER-2-positive (+) metastatic breast cancer (MBC) that progressed after trastuzumab (T).
  • <3 prior chemotherapy (CRx) regimens are permitted.
  • Therapy (tx) consists of C (2,000 mg BID, 7 - 7) and L (1,250 mg, daily).
  • Median (med) age 64 yrs (42-71), med ECOG PS 1 (0-1), ER/PR(+) 3, HER-2(+) 6, sites of MBC: bone (2), viscera (4), soft tissue (5).
  • CONCLUSIONS: Capecitabine (7 - 7) + lapatinib appears well tolerated compared to C(14 - 7)+L (Geyer et al).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962242.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Takahashi T, Yamamoto N, Murakami H, Ohe Y, Kunitoh H, Nokihara H, Koshiji M, Tamura T: A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):2572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2572 Background: Enz is an oral serine-threonine kinase inhibitor that is designed to suppress tumor growth through PKC and PI-3 kinase/AKT.
  • Cycle 1 started with a 7-day Enz lead-in treatment that preceded Pem administration: a loading dose of 1125 mg on day 1 followed by 500 mg total daily dose on days 2-7.
  • All pts had received prior platinum-based chemotherapy.
  • 5 pts received more than 10 cycles of treatment without disease progression; 4 of these pts are still on therapy.
  • CONCLUSIONS: Both schedules of Enz in combination with Pem are well tolerated and clinically active in pts with advanced NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Delaloge S, Tedesco KL, Blum J, Gonçalves A, Lubinski J, Efrat N, Osborne C, Lebedinsky C, Tercero JC, Holmes FA: Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):1010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T has EMEA authorization in soft tissue sarcoma after failure of standard treatment.
  • Preliminary data have shown activity of T as single agent in MBC.
  • Endpoints were objective response (OR) rate by RECIST, duration of response, progression free survival (PFS), tumor volume changes, safety and exploratory pharmacogenomics (PGx).
  • Med number of prior chemotherapy regimens: 4 (1-10).
  • Med number of T cycles administered: 2 (1-12) for all groups.
  • Tissue samples from 36 pts were collected for RNA expression analysis (XPG + ERCC1 + BRCA1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960738.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Hanna NH, Estes D, Arnott J, Marcotte S, Hannah A, Sidor CF, West H, Clamon G, Hoang T: Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
  • : e19005 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity against NSCLC cell lines including multi-drug resistant lines, and single agent activity in NSCLC pts.
  • This phase 1/2 study evaluated MKC-1 in combination with PEM as second-line therapy in pts with advanced NSCLC.
  • METHODS: Eligible pts had NSCLC previously treated with one regimen for metastatic disease or disease progression within one year following adjuvant and neoadjuvant therapy.
  • Following 4 cycles of combined treatment, single agent MKC-1 was continued as maintenance therapy.
  • Total # of treatment cycles to date for phase 2 pts is 95, with a median of 4 cycles.
  • Of the 19 phase 2 pts, 18 were evaluable for tumor response.
  • The combination is well tolerated with 17% of patients achieving a confirmed PR thus far.
  • A decision to proceed with additional accrual in this single arm study versus initiating a randomized phase 2 study of this combination is pending.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962522.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Arnold SM, Horn J, Eckardt JR, Rinehart JJ, DeSimone P, Fields SZ, Kee BK, Moscow JA, Houchins JC, Leggas M: Clinical and pharmacokinetic (PK) findings in a phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in patients with refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: AR-67 was infused over 1 hour for 5 days of a 21-day cycle using an accelerated titration phase I trial design.
  • PK was performed on the 1<sup>st</sup> and 4<sup>th</sup> day of cycle 1.
  • AR-67 was assayed with a validated chromatography method.
  • Median age 62 (range 31-79), 15M/11F, median prior therapies 3 (range 1 to 6).
  • Tumor types included: colorectal (8), non-small cell lung (NSCLC) (4), small cell lung (3), soft tissue sarcoma, (3), head and neck (2), prostate (2), and other (4).
  • 21 subjects completed 2 or more cycles of therapy, 5 subjects received 1 cycle of therapy and had rapid disease progression (1 received 2d of drug prior to PD), 1 subject is still under treatment after 9 cycles.
  • Common C1 worst-grade drug related toxicities (CTC I/II % vs III/IV %): Hg (27/8), WBC (11/19), ANC (19/8), platelets (19/12), fatigue (15/8) insomnia (8/0), flushing (15//0), constipation (8/0), nausea (23/0), ALT elevation (12/0), hiccups (8/0).
  • The lactone form was predominant in plasma (>85% of AUC) at all time points.
  • The RP2D is 7.5 mg/m<sup>2</sup>/day for 5 days of a 21-day cycle.
  • This work was supported by R21-CA-123867 and Arno Therapeutics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Yoshimatsu K, Yokomizo H, Otani T, Osawa G, Ogawa K: Phase I study of peptide vaccine with chemotherapy in patients with unresectable colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of peptide vaccine with chemotherapy in patients with unresectable colorectal cancer.
  • S-1/CPT-11 chemotherapy (CT) is reported to be obtained the similar result to FOLFOX or FOLFIRI as first-line for advanced CRC.
  • We plan phase I study to evaluate the safety of different doses of RNF43-721 emulsified with Montanide ISA51 in combination with S-1/CPT-11 CT expecting synergistic effect.
  • Other malignancy, infection, treatment with steroids and immunosuppressive agents, and HBV, HCV, HIV infection are excluded.
  • The study regimen is that oral administration of S-1 at 40 mg b.i.d. for 21 consecutive days followed by a 7-day rest period and intravenous infusion of CPT-11 at a dose of 80 mg on days 1 and 15 are performed with weekly subcutaneous injection of peptide vaccine.
  • Two courses are study periods and there is no restriction of therapy after study.
  • RESULTS: Twelve patients (pts) were enrolled and 3 pts canceled treatment due to patient's proposal.
  • Standard chemotherapy for CRC were failed in 8 pts.
  • CONCLUSIONS: Treatment with peptide vaccine and S-1/CPT-11 CT was well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM: High-Dose calcitriol, docetaxel, and estramustine in androgen-independent prostate cancer (AIPC): A phase I/II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4678

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to test the safety of a 3-drug regimen that combined docetaxel with estramustine and calcitriol.
  • Treatment was repeated every 21 days for up to 12 cycles.
  • A dose de-escalation scheme for calcitriol was planned if dose limiting toxicities were encountered during the first cycle of treatment in > 1/3 of patients.
  • 8 patients were chemotherapy-naïve and 12 had received prior docetaxel-based therapy (5 received more than 1 prior chemotherapy regimen).
  • The regimen was generally well tolerated and criteria for dose de-escalation were not met.
  • Treatment-related ≥ Grade 3 toxicity included: Hypophosphatemia- 4, Neutropenic fever - 2, perforated diverticulum - 1, edema - 1, vomiting - 1, ALT elevation - 1, anemia - 1, PTT elevation -1.
  • 3 patients had thromboembolic complications and one patient had grade 3 hematuria thought to be due to tumor.
  • 17 patients are evaluable for PSA response at this time.
  • 4 of 7 chemotherapy-naïve patients (57%) met criteria for PSA response (confirmed ≥ 50% decline).
  • There were no responses among the 3 patients treated with more than 1 prior chemotherapy regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015598.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Hersh EM, Weber J, Powderly J, Yellin M, Kahn K, Pavlick A, Samlowski W, Nichol G, O'Day S: A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):7511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In stage IV melanoma patients MDX-010 given with a gp100 vaccine demonstrated responses that correlated with autoimmune toxicity (Autoimmune Breakthrough Events; ABEs).
  • METHODS: 76 patients were enrolled and 72 received drug.
  • Responses were determined after 4 treatments.
  • RESULTS: The study arms were well balanced.
  • All ABEs but 1 resolved with treatment.
  • This study suggests that combination therapy with dacarbazine may have greater clinical activity than monotherapy in patients with Stage IV melanoma.
  • Future clinical trials of MDX-010 in combination with melanoma vaccines and chemotherapy are being planned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014885.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakayama N, Mashiko S, Yamazaki R, Kaneko N, Futagawa S, Nagaoka I: Evaluation of the distinction between responder and non-responder in FOLFOX/FOLFIRI based on the alteration of serum iron level. J Clin Oncol; 2009 May 20;27(15_suppl):e15110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15110 Background: The alteration of serum-iron level during chemotherapy is already reported (Follezou, NEOPLASMA 1985).
  • METHODS: Serum-iron levels, hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were analyzed in 58 aCRC / mCRC patients received FOLFOX-4 / FOLFIRI therapy between April 2005 and September 2008.
  • 26 patients received FOLFOX-4 / FOLFIRI therapy as the final chemotherapy died by the time of analysis.
  • RESULTS: Mean serum-iron levels in immediately pre and post chemotherapy were 71.7±29.0μg/dl and 186.8±83.2μg/dl, respectively, and significant increase after chemotherapy was observed (p<0.001).
  • This increase was transient and returns to pre chemotherapy level by the start of next course.
  • This alteration was always observed on the chemotherapy.
  • The median survival times from the initiation of FOLFOX-4 / FOLFIRI therapy for the high increase group (n: 5) and the low increase group (n: 21) were 487 and 182 days, respectively, and was significantly better in the high increase group (p=0.004).
  • The alterations of hemoglobin, AST and ALT serum levels in immediately pre and post chemotherapy were not observed.
  • Significantly better prognosis in high serum-iron group may suggest the usefulness of serum-iron level to distinguish responder and non-responder in FOLFOX-4/FOLFIRI therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960858.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I: Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer.
  • : e15599 Background: The role of the second line chemotherapy in advanced gastric cancer was not clear, but possibility of prolongation of survival is open question.
  • Irinotecan is promising agents in gastric cancer and this phase II study evaluated the efficacy and safety of combination chemotherapy with irinotecan, high dose of 5-fluorouracil (5-FU) and leucovorin in taxane and cisplatin based chemotherapy refractory metastatic gastric cancer.
  • All patients were evaluable for safety and survival and twenty seven patients (79.4%) were evaluable for tumor response.
  • CONCLUSIONS: This results showed that the combination chemotherapy with irinotecan, 5-FU and leucovorin was well tolerated and active in taxane and cisplatin refractory patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Kubota K, Kunitoh H, Seto T, Shimada N, Tsuboi M, Okamoto H, Masuda N, Maruyama R, Shibuya M, Watanabe K: A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503. J Clin Oncol; 2009 May 20;27(15_suppl):7561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503.
  • : 7561 Background: Adjuvant chemotherapy is standard of care for patients with completely resected stage IB, II and IIIA NSCLC.
  • However, the optimum chemotherapy regimen has not been determined.
  • Other eligibility criteria included ECOG PS 0-1, age ≥20, and =<70 years old, adequate organ function, no prior chemotherapy or radiotherapy.
  • Feasibility: 93% (54/58) of patients allocated to DC and 92% (49/53) patients in the PA arm completed 3 planned cycles of chemotherapy.
  • No treatment related deaths were observed in either arm.
  • CONCLUSIONS: Both docetaxel plus cisplatin and paclitaxel plus carboplatin are safe and feasible regimens as adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J: Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol; 2009 May 20;27(15_suppl):e13004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligibility included: adult patients with stable or recurrent MG (GBM, anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO]) previously treated with radiation therapy (RT) and with or without chemotherapy; interval of at least two weeks between prior RT, or four weeks between prior chemotherapy; Karnofsky ≥ 60%; and adequate hematologic, renal and liver function.
  • Patients were divided in two strata: those receiving enzyme-inducing antiepileptic drugs (EIAED) and those not receiving EIAED.
  • One patient is still on treatment, completing cycle 12.
  • CONCLUSIONS: SCH 66336 in combination with TMZ is well-tolerated and shows promising response when administered to patient when stable on TMZ alone or after RT and TMZ.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Okusaka T, Kasugai H, Ishii H, SM-11355 Japan Study Group: A randomized phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma.
  • : 4583 Background: SM-11355 (Miriplatin Hydrate) is a platinum complex developed to treat HCC via administration into the hepatic artery as a sustained-release formulation suspended in lipiodol.
  • METHODS: Patients with unresectable HCC were randomized 2:1 to receive an injection of SM-11355 or zinostatin stimalamer suspended in lipiodol into the hepatic artery at doses of up to 6 mL (SM-11355: 120 mg; zinostatin stimalamer: 6 mg) according to the tumor size.
  • Efficacy was evaluated by CT 3 months after treatment and categorized as therapeutic effect (TE) V to I.
  • The most frequent drug-related adverse events (AEs) of ≥ grade 3 (shown as SM-11355 vs. zinostatin stimalamer) were elevated AST (26.5 vs. 33.3%), elevated ALT (22.9 vs. 20.5%), thrombocytopenia (12.0 vs. 7.7%), and hyperbilirubinemia (9.6 vs. 5.1%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963097.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. McMeekin DS, Manikas G, Crispens M, Orza AM, Braly P, Doering D, Trifan OC, Michiels B, Markman M: A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma.
  • Activity in ovarian and other cancers suggested a use for ET-743 in the treatment of human endometrial carcinoma.
  • METHODS: Patients with measurable persistent or recurrent endometrial carcinoma after one prior chemotherapy regimen have been enrolled in this multicenter, open-label, phase II study.
  • ET-743 was administered as a 3 hour iv infusion every 21 days at a starting dose of 1.3 mg/m<sup>2</sup>.
  • Primary objective is the response rate; secondary endpoints are safety profile, time to progression, progression-free survival, and overall survival.
  • RESULTS: As of December 15, 2003, 23 patients received treatment.
  • Responses where the following: [Figure: see text] Eleven (47.83%) of the patients where treated within 3 months from their previous therapy.
  • One patient developed transient rhabdomyolysis, toxic hepatitis, dyspnea and upper GI hemorrhage.
  • CONCLUSIONS: ET-743 administered as a single agent in 3 hours infusion every 3 weeks is a reasonably well-tolerated drug with activity in endometrial carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015348.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Fuwa N, Kodaira T, Furutani K, Tatibana H, Toita T, Shikama N, Kano M, Hayasi N, Yuta A: Alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil - A preliminary report of phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):5613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Considering these characteristics of NPC, alternating chemoradiotherapy (ALT-CRT) may be a useful method of treating NPC because sufficient amount of anti-tumor agents can be administered together with a low frequency of mucositis compared to concurrent chemoradiotherapy (CRT).
  • Using 6 MV photon, RT was performed at an exposure of 1.8Gy 5 times a week.
  • That is, a total absorbed dose of 36 Gy was irradiated between the basal of skull and supraclavicular fossa.
  • One course of chemotherapy (CT) consisted of the administration of 5-FUdepends on document reviewat a dose of 800 mg/m<sup>2</sup>/24 h for 5 days (days 1-5) and CDDP at a dose of 50 mg/m<sup>2</sup>/24 h for 2 days (days 6-7), and a total of 3 courses of CT was performed.
  • In these 67 patients, the overall 3-year survival rate was 93%, and the progression free survival rate was 80% (The median follow up times was 33 months).
  • CONCLUSIONS: This method of ALT-CRT yielded higher or at least similar survival rate and lower toxicities than concurrent CRT, and we believed that this method can be used in a controlled clinical trial in the future to compare therapeutic results with those of the Intergroup 0099 Trial No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015269.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Aliberti S, Grignani G, Allione P, Porrino G, Fizzotti M, Carnevale Schianca F, Rota Scalabrini D, Galatola G, Pisacane A, Aglietta M: Autoimmune Hepatitis - Overlap Syndrome (AH) occurring during imatinib therapy in a gastro-intestinal stromal tumor (GIST) patient. J Clin Oncol; 2004 Jul 15;22(14_suppl):9064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune Hepatitis - Overlap Syndrome (AH) occurring during imatinib therapy in a gastro-intestinal stromal tumor (GIST) patient.
  • We describe the development of a chronic hepatitis in an Imatinib responsive GIST patient.
  • METHODS: A 65-year-old caucasian male presented with a GIST peritoneal spread.
  • A partial response was achieved after two months of treatment.
  • At that time a progressive increase of aminotransferases (AST and ALT) without any other clinical sign of liver toxicity or GIST progression was detected.
  • Liver infections, drug abuse and metabolic diseases were excluded.
  • CONCLUSIONS: A moderate increase of ALT is a well recognized and reversible Imatinib toxicity.
  • AH is responsive to steroid therapy and does not require to stop Imatinib for full recovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014080.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Poole CJ, Howard HC, Hiller L, Dunn JA, Wardley AM, Bowman A, Coleman RE, Fernando IN, Ritchie DM, Earl HM: A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in 'tAnGo': A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):821

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in 'tAnGo': A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide (EC)-based, adjuvant chemotherapy (CT) for early stage breast cancer.
  • : 821 Background: tAnGo is an ongoing 3000-patient (pt) randomized trial evaluating for the first time the role of G in adjuvant CT for breast cancer.
  • We present the results of a preliminary prospective safety study designed to assess the incidence of any treatment (trt)-related clinical or sub-clinical disturbances of pulmonary, cardiac, or hepatic fn in the first 135 pts randomised.
  • RESULTS: Pulmonary fn tests: majority normal at all time points, with no differences between trts or changes over time in FEV<sub>1</sub> (p>0.3 and 0.9 resp) or FVC (p=0.95 and 0.5 resp).
  • 94% of all CXRs normal with no differences between trts (p>0.25) and no changes over time (p=0.14).
  • Cardiac fn tests: 95% of all Echo/MUGA scans and 90% of all ECGs normal, with no differences between trts (p>0.35 and >0.25 resp) and no changes in Echo/MUGAs over time (p=0.4); only a slight time effect in ECGs (p=0.03).
  • Hepatic fn tests: 92% of all AST levels and 82% of all ALT levels normal (majority of abnormal results graded 1/2): EC+T pts show a modest increase in transaminases at mid-CT but this resolves by post-CT (AST p=0.08 and ALT p=0.38 for change over time); transaminase increases in EC+GT pts persist post-CT but resolve by 6 months (AST p=0.004 and ALT p=0.001 resp for change over time).
  • Acute skin toxicity during RT: 87% of reports graded this as Nil/Mild; only 1% as severe; no difference between trts (p>0.1), although severity increased over time (p<0.0001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014323.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Yoshida T, Murakami H, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H: CPT-11 + CDDP in patients with metastatic and recurrent gastric cancer as a third-line chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):4204

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPT-11 + CDDP in patients with metastatic and recurrent gastric cancer as a third-line chemotherapy.
  • : 4204 Background: Among the patients with gastric cancer for whom two consecutive chemotherapy have failed, some still hold good performance status (PS) and organ function and may benefit from further cytotoxic therapy.
  • The response rate (RR) and toxicity of CPT-11 + CDDP in patients treated with two regimens of prior chemotherapy is assessed retrospectively.
  • All had received TS-1 (80mg/m<sup>2</sup>, on day 1-28 every 6 weeks) as a first line, and weekly paclitaxel (80mg/m<sup>2</sup>, on day 1, 8, 15 every 28 days) as a second line chemotherapy.
  • There were no treatment-related deaths.
  • Median survival time after initiation of CPT-11/CDDP was 214 days (range: 29-366).
  • CONCLUSIONS: As a third line chemotherapy, CPT-11/CDDP may benefit patients with relatively good PS in terms of survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013932.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Raymond E, Brandes A, Van Oosterom A, Dittrich C, Fumoleau P, Coudert B, Twelves C, De Balincourt C, Lacombe D, Van Den Bent M: Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study. J Clin Oncol; 2004 Jul 15;22(14_suppl):1501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 1501 Background: Autocrine activation of PDGFα&β receptors yields strong mitogenic effects and activates tumor angiogenesis in malignant gliomas.
  • Preclinical data showed tumor growth inhibition of ras and v-sis transformed BALB/c, 3T3U87 and U343 human glioma xenografts in mice using imatinib mesylate.
  • METHODS: To assess the antitumor activity (measured by response and 6-month PFS) and the safety of imatinib mesylate (Glivec) in patients (pts) with histologically proven, CT-scan or MRI documented measurable recurrent glioblastoma, stable/decreasing doses of steroids, no more than one prior chemotherapy regimen, and no surgery or radiotherapy within 3 months prior to enrollment were entered.
  • Imatinib mesylate was given until tumor progression at the daily dose of 600mg (group A) and 800mg (group B) in two cohorts of pts.
  • A Fleming one sample/one stage testing procedure was used.
  • 33 pts had been exposed to chemotherapy, 50 to radiotherapy, and 45 had prior resection.
  • One patient presented an intratumoral hemorrhage associated with a documented tumor progression (considered not related to treatment).
  • Responses slowly occurred after 3, 6 and 7 months of drug exposure.
  • Prolonged ≥6-months tumor stabilizations were reported in 5 pts (1 in group A and 4 in group B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015385.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Colomer R, Mayordomo JI, Calvo L, Hornedo J, Carabantes F, Gil M, Martin B, Cortes-Funes H: Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):740

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The GTH regimen was paclitaxel 150 mg/m2 followed by gemcitabine 2500 mg/m2, both on Day 1 of a 14-day cycle, maximum of 10 cycles, and trastuzumab 2 mg/kg weekly, with a loading dose of 4 mg/kg, administered the day before the first chemotherapy dose.
  • Median age at diagnosis was 51 years; median performance status was 90; median number of metastatic sites was 2.
  • Most patients (74%) had prior adjuvant chemotherapy, usually involving anthracyclines (68%).
  • HER2 ECD is a valuable method to select for trastuzumab therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Kolevska T, Ryan CJ, Huey V, Weisberg L, Wang S, Baer D, Ghadialy A, Goldstein D, Fireman B, Fehrenbacher L: Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5152

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC).
  • : 5152 Background: Many patients with hormone refractory prostate cancer have poor tolerance to treatment.
  • Docetaxel chemotherapy was shown to improve survival but has substantial toxicity, requires steroid administration, may cause poorly reversible neuropathy and requires long infusion times, all limiting its use.
  • Nab-paclitaxel, an albumin-bound nanopaticle form of paclitaxel, delivers paclitaxel without steroids, requires only 30 minutes infusion time and has favorable toxicity profile that may be more tolerable but effective in patients with prostate cancer.
  • The goal of this study was to evaluate the efficacy and toxicity of nab-paclitaxel in first line chemotherapy of men with castration resistant prostate cancer.
  • Main eligibility criteria include: hormone refractory metastatic prostate cancer, no prior chemotherapy, performance status 0-2.
  • One patient discontinued the treatment after 1 infusion due to toxicity (elevated ALT).
  • Seven patients received treatment for ≥ 6 months with minimal toxicity (range 6-10 months).
  • This regimen was well tolerated, and may be useful in patients who are not suitable candidates for docetaxel based therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964449.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Rougier P, Infante J, Van Laethem J, Stephenson JJ, Uronis H, Schwartzberg L, Chen L, Wu C, Smethurst D, Peeters M: A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results. J Clin Oncol; 2009 May 20;27(15_suppl):4130

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results.
  • METHODS: Eligible patients (pts) were ≥ 18 years old, had ECOG status 0-1, radiographic disease progression (PD) during or after tx with fluoropyrimidine, irinotecan, and/or oxaliplatin chemotherapy for mCRC.
  • In part 1, pts received pmab 6 mg/kg Q2W plus AMG 655 at a starting dose of 10 mg/kg (evaluation of subsequent doses of 3 mg/kg or 1 mg/kg if needed; 6-9 pts at each dose) by sequential intravenous infusion at week 1 and Q2W thereafter until PD or intolerability.
  • Median (range) follow-up time was 15.4 (9-31) weeks.
  • Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area;.
  • (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.
  • Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960839.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Baker SD, Ten Tije AJ, Carducci MA, Gelderblom H, Dawkins FW, McGuire WP, Verweij J: Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance. J Clin Oncol; 2004 Jul 15;22(14_suppl):2006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2006 Background: Docetaxel exhibits wide interindividual variation in drug clearance (CL).
  • METHODS: PK studies were performed during cycle 1 of therapy in 58 cancer pts.
  • Pre-treatment CYP3A activity was determined using the erythromycin breath test (ERMBT).
  • Log-transformed CYP3A correlated well with docetaxel CL in all pts (R = 0.48; P = .0001).
  • CONCLUSIONS: LF alone does not explain variability in drug CL.
  • These data indicate that CYP3A activity is an additional predictive covariate for drug CL and may deserve consideration as a factor in dose calculation for docetaxel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015782.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Krown SE, Hwu WJ, Menell JH, Panageas KS, Lamb LA, Aird S, Williams LJ, Chapman PB, Livingston PO, Wolchok JD: A phase II study of temozolomide (TMZ) and pegylated interferon α-2b (PGI) in the treatment of advanced melanoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):7533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of temozolomide (TMZ) and pegylated interferon α-2b (PGI) in the treatment of advanced melanoma.
  • : 7533 Background: Interferon-α (IFN) has some anti-tumor activity against melanoma, but has been used primarily at high, toxic doses.
  • We hypothesized that low-dose PGI might act additively or synergistically with the cytotoxic agent, TMZ in the treatment of malignant melanoma.
  • A phase II study of this combination was initiated in chemotherapy-naïve melanoma patients (pts) to determine response rate and toxicity.
  • 24 pts have completed at least 1 treatment cycle.
  • There were 7 major responses (29%), including 1 CR in soft tissue and liver and 6 PRs in lung, other viscera, soft tissue and lymph nodes.
  • CONCLUSIONS: The combination of TMZ with low-dose PGI is well tolerated and effective in patients with advanced melanoma without brain metastases and merits further study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014922.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Funakoshi A, Okusaka T, Ishii H, Sawaki A, Ohkawa S, Ishikawa O, Saitoh S: Phase II study of irinotecan (CPT-11) alone in patients (pts) with metastatic pancreatic cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):4102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Chemotherapy naive pts with metastatic pancreatic cancer who fulfilled the following criteria were registered: measurable metastatic disease, KPS≥50, age<75, ANC≥2000, Hgb≥10, Plts≥100K, AST&ALT≤2.5X nl, t-bili≤2.0, adequate organ function, and written informed consent.
  • The median survival time was 7.3 months.
  • Obstructive jaundice, elevated bilirubin and gastric variceal bleeding also occurred as drug unrelated SAE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014506.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: [Indication of chemotherapy according to histological type of musculoskeletal sarcomas]. Gan To Kagaku Ryoho; 2009 Feb;36(2):199-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.
  • Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.
  • On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.
  • The efficacy is evaluated by reduction of the tumor volume as a surrogate marker.
  • Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.
  • Among them, the key drugs are adriamycin and ifosfamide.
  • For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.
  • Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.
  • Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


52. May M, Seehafer M, Helke C, Gunia S, Hoschke B: [Liposarcoma of the spermatic cord--report of one new case and review of the literature]. Aktuelle Urol; 2004 Apr;35(2):130-3
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma of the spermatic cord--report of one new case and review of the literature].
  • [Transliterated title] Liposarkom des Samenstrangs--Darstellung eines Falls.
  • Liposarcoma of the spermatic cord is a rare entity.
  • Although most liposarcomas of the spermatic cord are well-differentiated, the propensity for local recurrence is high.
  • Preferential treatment of spermatic cord liposarcoma is radical orchiectomy with high ligation of the cord.
  • Radiation therapy is recommended in addition to surgery in cases with evidence of more aggressive tumour behavior (i.e., high-grade tumour, lymphatic invasion, inadequate margin, or recurrence).
  • A 39-year-old-male presented with a 4-year history of a mass in the left scrotum.
  • Pathological analysis demonstrated a well-differentiated liposarcoma with tumour detection in the surgical margin.
  • In view of the incomplete surgical removal of the tumour a retroperitoneal reoperation of the testicular vessels and vas deferent with R0-resection was conducted.
  • Without any postoperative adjuvant therapy in evidence of recurrence or metastasis was noted during the 12-month follow-up period.
  • Paratesticular liposarcomas are most commonly well-differentiated and lipoma-like and have a prolonged clinical course.
  • Radical orchiectomy with wide local excision of the mass is the recommended therapy, while adjuvant radiotherapy may be considered in high-grade tumours and in recurrent liposarcomas.
  • Retroperitoneal lymphadenectomy does not offer any additional therapeutic benefit, and the role of chemotherapy is not well defined.
  • Regardless of initial therapy, the risk of local recurrence always necessitates long-term followup.
  • [MeSH-major] Genital Neoplasms, Male. Liposarcoma. Spermatic Cord
  • [MeSH-minor] Adult. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Orchiectomy. Radiotherapy, Adjuvant. Reoperation. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15146377.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Italiano A, Delva F, Mathoulin-Pelissier S, Le Cesne A, Bonvalot S, Terrier P, Trassard M, Michels JJ, Blay JY, Coindre JM, Bui B: Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol; 2010 Dec;21(12):2436-41
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database.
  • BACKGROUND: The predictive value of grade for benefit from adjuvant chemotherapy (AC) in soft tissue sarcoma (STS) patients has never been explored.
  • Grade was assessed according to the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system after central review.
  • Young age, non-well-differentiated liposarcoma histology, deep location, bone and/or neurovascular invasion and grade 2 or 3 were significantly associated with a higher likelihood to receive AC.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439343.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


54. Okby NT, Travis WD: Liposarcoma of the pleural cavity: clinical and pathologic features of 4 cases with a review of the literature. Arch Pathol Lab Med; 2000 May;124(5):699-703
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the pleural cavity: clinical and pathologic features of 4 cases with a review of the literature.
  • BACKGROUND: Primary liposarcomas of the pleura are extremely rare malignancies, and relatively few reports appear in the world literature.
  • DESIGN: We compiled a small series of 4 cases of primary pleural liposarcoma from the files of the Armed Forces Institute of Pathology (Washington, DC) and compared the histopathologic and clinical features of these 4 cases with those of 9 previously published cases.
  • Histologic subtypes in the 9 cases with available information included 5 myxoid liposarcomas, 1 well-differentiated liposarcoma, and 3 liposarcomas with mixtures of histologic types.
  • Surgical resection with or without chemotherapy appeared to be the most common form of treatment, although radiation therapy was used in some cases and seemed beneficial.
  • Survival information was available for 11 cases; 4 patients died of disease at 7, 9, 12, and 19 months; 1 died of heart failure 2 days after presentation; 1 died of unknown causes 16 months after presentation; and 3 patients were alive without tumor at 5, 16, and 66 months after diagnosis.
  • CONCLUSIONS: Primary pleural liposarcomas occur predominantly in older men, and the myxoid histologic subtype is the most common.
  • Radiographic or surgical evaluation is important to distinguish primary pleural liposarcoma from chest wall or mediastinal sarcomas, as well as metastases from other sites.
  • Although further investigation is needed, evidence from the cases reviewed here indicates that surgical resection with adjuvant radiation therapy may benefit patients with primary pleural liposarcoma.
  • [MeSH-major] Liposarcoma / pathology. Liposarcoma, Myxoid / pathology. Pleura / pathology. Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782150.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 15
  •  go-up   go-down


55. Bradley JC, Caplan R: Giant retroperitoneal sarcoma: a case report and review of the management of retroperitoneal sarcomas. Am Surg; 2002 Jan;68(1):52-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent resection of a well-differentiated liposarcoma arising from his retroperitoneum measuring 50 cm and weighing 11.7 kg (25.8 lb).
  • This is the second largest retroperitoneal soft-tissue sarcoma (RSTS) that has been reported.
  • Over the last 15 years 1123 patients with RSTS in 25 series have been reported with a mean tumor size of 15.7 cm.
  • Diagnosis and treatment of RSTS can be extremely challenging for a general surgeon.
  • Symptoms are nonspecific and may occur only after the tumor is very large.
  • Treatment of RSTS remains surgical.
  • Multiple trials of chemotherapy and radiation therapy show no survival benefit.
  • The only successful treatment of this tumor is complete excision; 51.4 per cent of tumors can be completely excised, and 50.2 per cent of these excisions include adjacent organs.
  • With aggressive surgical therapy survival is increased to 58.0 and 39.6 per cent.
  • [MeSH-major] Liposarcoma / surgery. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12467318.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


56. Jones RL, Fisher C, Al-Muderis O, Judson IR: Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer; 2005 Dec;41(18):2853-60
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential sensitivity of liposarcoma subtypes to chemotherapy.
  • Liposarcoma is one of the most common soft tissue sarcomas and has a number of different subtypes: well-differentiated; dedifferentiated; myxoid/round cell; and pleomorphic.
  • However, the response of these subgroups to chemotherapy is not well documented.
  • In this study, we have conducted a retrospective analysis of a prospectively maintained database of soft tissue sarcoma patients treated at the Royal Marsden Hospital.
  • Eighty-eight liposarcoma patients who received chemotherapy between August 1989 and June 2004 were identified.
  • The response rates to chemotherapy of the different histological subtypes and overall and progression free survival were investigated.
  • A statistically significant higher response rate to first-line chemotherapy was observed in patients with myxoid liposarcoma compared to de- and well-differentiated tumours, 48% (95%CI; 28-69) and 11% (95%CI; 2-29), P = 0.005.
  • Similarly, those with myxoid liposarcoma had a significantly higher response rate compared to all other liposarcoma patients, 48% (95%CI; 28-69) and 18% (95%CI; 8-31).
  • This retrospective analysis suggests that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, and in particular de- and well-differentiated tumours.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Liposarcoma, Myxoid / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289617.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


57. Buyukhatipoglu H, Sevinc A, Camci C, Buyukberber S, Sari I: A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation. Clin Lab Haematol; 2006 Oct;28(5):343-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation.
  • Dedifferentiated and well-differentiated liposarcomas are the two pathological subtypes of liposarcoma, based on the WHO classification.
  • Transition from well-differentiated to dedifferentiated liposarcoma is a well-recognized phenomenon.
  • Well-differentiated tumors are known to have low malignancy grade.
  • However, when dedifferentiation occurs, the tumor acquires the aggressive features of a fully malignant lesion.
  • This process largely is believed to progress in a time-dependant manner; however, time is not the only factor of importance.
  • To date, the coexistence of AML and liposarcoma has not been reported in the literature.
  • In this paper, we report on a case of coexistence of AML and liposarcoma, and on the unusual behavior of a well-differentiated tumor after dedifferentiation occurs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Liposarcoma / chemically induced

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999727.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Calleja Subirán MC, Hernández Gutiérrez FJ, López Elzaurdia C, Revestido García R: [Liposarcoma histologic subtypes: four cases reports]. An Med Interna; 2007 Apr;24(4):179-84
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma histologic subtypes: four cases reports].
  • [Transliterated title] Subtipos histológicos de liposarcoma: presentación de cuatro casos.
  • The liposarcoma is a malignant tumor of mesodermic origin derived of the adipose tissue.
  • Liposarcoma s types, according to his histological diagnosis, are: mixoide, pleomorphic, well differentiated and dedifferentiated.
  • His treatment is the radical surgery, it is possible, together with radiation therapy and/or chemotherapy.
  • Four patients diagnosed of liposarcoma are shown up, a case of liposarcoma well differentiated, another case of liposarcoma pleomorphic and two cases about liposarcoma mixoide; with the characteristic that one of these two cases presented a local recidivation with a dediferenciation of itself.
  • The evolution of the four cases, was in a different way.
  • [MeSH-major] Abdominal Neoplasms / pathology. Liposarcoma / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Abdomen / pathology. Aged. Diagnosis, Differential. Female. Humans. Liposarcoma, Myxoid / diagnosis. Liposarcoma, Myxoid / pathology. Liposarcoma, Myxoid / radiography. Liposarcoma, Myxoid / surgery. Male. Middle Aged. Prognosis. Radiography, Abdominal. Retroperitoneal Space / pathology. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867902.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


59. Peyrí Rey E, Urban Ramón A, Martínez Fernández M, Sanmarti Da Silva B: [Dedifferentiated liposarcoma of spermatic cord: degeneration of lipoma previously resected]. Actas Urol Esp; 2003 May;27(5):383-6
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dedifferentiated liposarcoma of spermatic cord: degeneration of lipoma previously resected].
  • [Transliterated title] Liposarcoma dediferenciado del cordón espermático: degeneración de un lipoma previo resecado.
  • Dedifferentiated liposarcoma accounts for only 10% of all spermatic cord sarcomas.
  • These are usually large-sized tumours histologically characterised for being well-differentiated liposarcomas with some high grade sarcoma areas.
  • Volume, location, mass homogeneity as well as presence of pelvic and retroperitoneal adenopathies are reported by CT and ultrasound techniques.
  • These are useful for post-treatment follow-up.
  • This paper presents one spermatic cord, dedifferentiated liposarcoma from which lipomas from the same spermatic cord had been previously removed in three occasions.
  • We believe this is a degeneration of the earlier resected lipoma.
  • Value of adjuvant radio- and chemotherapy is uncertain.
  • [MeSH-major] Genital Neoplasms, Male / pathology. Lipoma / pathology. Liposarcoma / pathology. Spermatic Cord / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12891917.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


60. Montgomery E, Fisher C: Paratesticular liposarcoma: a clinicopathologic study. Am J Surg Pathol; 2003 Jan;27(1):40-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular liposarcoma: a clinicopathologic study.
  • Paratesticular liposarcomas are rare and typically reported as isolated cases or as components of larger studies of liposarcomas.
  • All cases of paratesticular liposarcomas were retrieved from the archives of the Royal Marsden Hospital and the Johns Hopkins Hospital.
  • There were 30 paratesticular liposarcomas from men aged 41-87 years (mean 63 years; median 65 years) that involved the spermatic cord (23, 76%), testicular tunics (6, 20%), and epididymis (1, 4%).
  • Nineteen were well-differentiated liposarcomas (WDLs) and 10 were dedifferentiated liposarcomas (DDLs, five with high-grade and five with low-grade dedifferentiation).
  • One was a myxoid/round cell liposarcoma with 70% round cell areas.
  • One patient with WDL received radiation after his second recurrence and the myxoid/round cell liposarcoma received radiation and chemotherapy.
  • Follow-up information was available for 16 of the patients, including 10 WDLs (range 24-216 months, mean 106 months), 5 DDLs (14-30 months, median 24 months), and for the myxoid/round cell liposarcoma (14 months) (range for all cases 14 months to 22 years; mean 87 months, median 36 months).
  • Six of the WDLs (60%) recurred at 2, 4, 6, 10, 18, and 21 years (median 8 years).
  • One patient with WDL had two recurrences at 4 and 7 years, and another had six recurrences over a 17-year period.
  • Only one example of DDL recurred, at 30 months; another patient, who refused therapy for 15 years, had a primary tumor 30 cm in diameter, displayed pulmonary metastases 1 month after excision, and died after 14 months.
  • In summary, paratesticular WDL had a prolonged course with recurrences in more than half the cases, sometimes late.
  • One DDL recurred and only one of five (20%) developed metastases, but the mean follow-up for DDL was only 24 months.
  • [MeSH-major] Liposarcoma / secondary. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12502926.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Chibon F, Mariani O, Derré J, Mairal A, Coindre JM, Guillou L, Sastre X, Pédeutour F, Aurias A: ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. Genes Chromosomes Cancer; 2004 May;40(1):32-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications.
  • This genetic finding, very similar to that in well-differentiated liposarcomas, strongly suggests that these tumors actually correspond to undifferentiated liposarcomas.
  • Our findings demonstrate that amplification and overexpression of ASK1 (MAP3K5), a gene localized in the 6q23 band and encoding a mitogen-activated protein kinase kinase kinase of the JNK-MAPK signaling pathway, could inhibit the adipocytic differentiation process of the tumor cells.
  • Treatment of a cell line with specific inhibitors of ASK1 protein resulted in the bypass of the differentiation block and induction of a strong adipocytic differentiation.
  • These observations indicate that ASK1 is a target for new therapeutic management of these aggressive tumors.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 6 / genetics. Gene Amplification / genetics. Histiocytoma, Benign Fibrous / drug therapy. MAP Kinase Kinase Kinases / antagonists & inhibitors. MAP Kinase Kinase Kinases / physiology. Retroperitoneal Neoplasms / drug therapy
  • [MeSH-minor] Adipocytes / drug effects. Adipocytes / pathology. Aged. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cell Line, Tumor. Enzyme Inhibitors / pharmacology. Female. Humans. Liposarcoma / drug therapy. Liposarcoma / enzymology. Liposarcoma / genetics. MAP Kinase Kinase Kinase 5. MAP Kinase Signaling System / drug effects. MAP Kinase Signaling System / genetics. Male. Middle Aged. Nucleic Acid Hybridization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15034865.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.11.25 / MAP Kinase Kinase Kinase 5; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP3K5 protein, human
  •  go-up   go-down


62. Blom E, Heyning FH, Kroes WG: A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1). Cancer Genet Cytogenet; 2010 Oct 1;202(1):38-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).
  • Acquired neocentromeres have been described in a particular class of lipomatous tumors (atypical lipomas and well-differentiated liposarcomas; ALP-WDLPS), three cases of acute myeloid leukemia (AML), one case of non-Hodgkin lymphoma (NHL), and one case of lung carcinoma.
  • Cytogenetic analysis of his bone marrow showed multiple aberrations, including the presence of a supernumerary chromosome.
  • It represented an inverted duplication of the segments between 1q21 and 1qter with a neocentromere in band 1q31.
  • To our knowledge, this is the second reported case of NHL (both T-cell) with the presence of a neocentromere.
  • The occurrence of neocentromeres in tumor cells, however, may be underestimated because of technical limitations during the routine diagnostic chromosomal analysis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Inversion. Chromosomes, Human, Pair 1. Gene Duplication. Immunoblastic Lymphadenopathy / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Neoplasms, Second Primary. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20804919.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


63. Carrión López P, Pastor Navarro H, Martínez Ruiz J, Giménez Bachs JM, Donate Moreno MJ, Polo Ruiz L, Pastor Guzmán JM, Martínez Sanchiz C, Ruiz Mondéjar R, Virseda Rodríguez JA: [Spermatic cord sarcomas: current status and report of four cases]. Arch Esp Urol; 2009 Apr;62(3):242-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study and review spermatic cord sarcomas, including symptoms, diagnosis, and treatment.
  • METHODS/RESULTS: We review the Spanish and international literature and report 4 new cases: 2 patients with well-differentiated spermatic cord liposarcomas (1 treated by simple tumorectomy), 1 patient with liposarcomatous degeneration of a previously excised atypical lipoma, and 1 patient operated for a malignant retroperitoneal fibrous histiocytoma with subsequent local recurrence in the paratesticular region.
  • They are diagnosed by imaging studies (ultrasound, computed tomography, magnetic resonance) and confirmed by histological examination.
  • Spermatic cord sarcomas are treated surgically; the efficacy of adjuvant treatments such as chemotherapy or radiation therapy is still under debate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554782.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


64. Dalal KM, Antonescu CR, Singer S: Diagnosis and management of lipomatous tumors. J Surg Oncol; 2008 Mar 15;97(4):298-313
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of lipomatous tumors.
  • Lipomatous tumors range from benign lipomas to high-grade liposarcomas.
  • Liposarcomas are classified into five histologic subtypes: well-differentiated, dedifferentiated, myxoid, round cell, and pleomorphic, which differ in outcomes and patterns of recurrence.
  • Surgical resection is the mainstay of curative treatment; however, large, high grade liposarcomas may benefit from multimodality treatment with chemotherapy and radiation.
  • Prospective randomized clinical trials will continue to improve our care of patients with liposarcoma.
  • [MeSH-major] Liposarcoma / diagnosis. Liposarcoma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Lipoma / diagnosis. Lipoma / pathology. Lipoma / therapy. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18286473.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 84
  •  go-up   go-down


65. Kalyvas KD, Kotakidou R, Trantos A, Yannakoyorgos K, Hatzichristou DG: Paratesticular well-differentiated, adipocytic type liposarcoma presenting as inguinal hernia. Urol Int; 2004;72(3):264-8
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular well-differentiated, adipocytic type liposarcoma presenting as inguinal hernia.
  • Paratesticular masses can pose difficult diagnostic and therapeutic problems to the physician.
  • We report a rare case of paratesticular liposarcoma with the clinical symptomatology of an inguinal hernia.
  • The treatment was surgical and included radical orchiectomy and wide excision of the tumor mass to the macroscopically healthy margins.
  • The patient is well and with no evidence of recurrence 1 year after the operation.
  • We review the literature, and discuss the role of radical orchiectomy, radiation, and chemotherapy in the treatment of paratesticular liposarcomas.
  • [MeSH-major] Hernia, Inguinal / etiology. Liposarcoma / complications. Testicular Neoplasms / complications

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 15084775.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 17
  •  go-up   go-down


66. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The approach to the management of retroperitoneal tumors begins with a complete history and physical examination.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI).
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


67. Gritli S, Khamassi K, Lachkhem A, Touati S, Chorfa A, Ben Makhlouf T, El May A, Gammoudi A: Head and neck liposarcomas: a 32 years experience. Auris Nasus Larynx; 2010 Jun;37(3):347-51
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck liposarcomas: a 32 years experience.
  • OBJECTIVE: The aim of this review is to study natural history, presentation, treatment and prognosis of head and neck liposarcomas.
  • Therapeutic modalities included surgery, radiotherapy and chemotherapy.
  • Histological types of liposarcomas were the following: myxoid (5 cases), well differentiated (4 cases), pleomorphic (4 cases), round cell (1 case) and dedifferentiated (1 case).
  • After initial treatment, complete remission was achieved in 7 cases (46.7%).
  • Two of these patients were reoperated and another one received chemotherapy.
  • In the other 5 cases, the tumor was uncontrollable and no additional treatment has been proposed.
  • CONCLUSION: The mainstay of treatment of head and neck liposarcomas is surgical excision and the prognosis is largely determined by the histological grade and the clinical stage.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Liposarcoma / pathology. Liposarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19857936.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


68. Lahat G, Anaya DA, Wang X, Tuvin D, Lev D, Pollock RE: Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol; 2008 Jun;15(6):1585-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.
  • BACKGROUND: Division of retroperitoneal liposarcoma (RPLS) into well-differentiated (WD) and dedifferentiated (DD) subtypes is established; however, WD and DD are usually treated similarly.
  • We hypothesized that WD and DD have distinct biological behaviors mandating different treatments.
  • A significant proportion of DD (37.7%) received chemotherapy compared to WD (1.7%; p < 0.0001).
  • Median time to recurrence was 55.5 months in WD versus 13.5 months in DD (p < 0.0001).
  • Treatment should therefore reflect these biologic differences by maximizing survivorship while avoiding unnecessarily extensive multivisceral resection.
  • SYNOPSIS: The biological behaviors of well-differentiated and dedifferentiated liposarcomas differ significantly.
  • This article presents outcomes of two different surgical approaches that were implemented at the UTMDACC, treating these tumors as different disease entities.
  • [MeSH-major] Liposarcoma / pathology. Liposarcoma / surgery. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jun;15(6):1555-6 [18347875.001]
  • (PMID = 18398663.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Cho SH, Rhim SC, Hyun SJ, Bae CW, Khang SK: Intradural involvement of multicentric myxoid liposarcoma. J Korean Neurosurg Soc; 2010 Sep;48(3):276-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intradural involvement of multicentric myxoid liposarcoma.
  • Liposarcomas are malignant tumors of the soft tissue, with myxoid liposarcoma being the second most common subtype, tending to occur in the limbs, particularly in the thighs.
  • Myxoid liposarcomas have an intermediate prognosis between well-differentiated and pleomorphic tumors.
  • We present an unusual case of a multicentric myxoid liposarcoma with intradural involvement.
  • She was histologically diagnosed with small round cell myxoid sarcoma and underwent adjuvant chemotherapy.
  • However, the patient died of multiple metastases 18 months after the first diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082059.001).
  • [ISSN] 1598-7876
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2966733
  • [Keywords] NOTNLM ; Cervical spine / Metastasis / Multicentric / Myxoid liposarcoma / lntradural
  •  go-up   go-down


70. Thanakit V, Nelson SD, Udomsawaengsup S: Round cell liposarcoma of scrotum with indolent course in young adult. J Med Assoc Thai; 2005 Sep;88(9):1302-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Round cell liposarcoma of scrotum with indolent course in young adult.
  • Myxoid/Round cell liposarcoma accounts for one-half of all liposarcomas and occurs as the second most common subtype.
  • Both myxoid and round cell types share clinical, histological features and are accepted to represent a spectrum of lesions ranging from pure myxoid to near completely round cell liposarcoma.
  • Round cell liposarcoma is highly metastatic and is classified as high grade and poorly differentiated myxoid sarcoma.
  • Typical non-round cell myxoid liposarcoma is less metastatic and has more favorable prognosis.
  • Karyotypic study of myxoid and round cell liposarcomas reveal a characteristic reciprocal translocation t (12;16)(q13;p11) resulting in the fusion of CHOP gene with TLS gene in more than 90% of cases.
  • Most masses within the scrotal sac arise from the testis proper, and less likely from the extratesticular tissue.
  • Liposarcoma represents approximately 20% of malignant extratesticular neoplasms, with the well differentiated subtype being the most common.
  • Myxoid/round cell liposarcoma and round cell liposarcoma are rarely encounter in extratesticular soft tissue.
  • We reported a rare case of round cell liposarcoma (high grade myxoid liposarcoma) of extratesticular tissue.
  • To our knowledge, this is the first case of a large size (> 5cm) round cell liposarcoma arising from soft tissue within the scrotal sac of young adult with indolent course.
  • Simple excision or enucleation are inadequate therapies and wide excision of the hemiscrotum including inguinal soft tissue and nodes is recommended.
  • The role of retroperitoneal lymph node dissection and adjuvant chemotherapy remains controversial.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Liposarcoma, Myxoid / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Prognosis. Scrotum / pathology. Testicular Hydrocele / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536120.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


71. Madge SN, Tumuluri K, Strianese D, Bonavolonta P, Wilcsek G, Dodd TJ, Selva D: Primary orbital liposarcoma. Ophthalmology; 2010 Mar;117(3):606-14
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary orbital liposarcoma.
  • PURPOSE: To describe 6 new cases of primary orbital liposarcoma and provide a review of the relevant literature.
  • PARTICIPANTS: Six patients with primary orbital liposarcoma.
  • MAIN OUTCOME MEASURES: Patient demographics; clinical presentations; results of radiologic imaging; histopathology; surgical techniques used and their complications; other treatment modalities; outcomes and recurrences.
  • RESULTS: Six cases of primary orbital liposarcoma were identified, 5 of which were primary presentations and 1 of which was a recurrence.
  • Literature review identified 34 other cases of primary orbital liposarcoma, which, partly because of its rarity, is frequently initially misdiagnosed.
  • The most common subtype is myxoid (56.8%); other types are pleomorphic (10.8%) and well differentiated (29.7%).
  • Well-differentiated tumors have the best prognosis.
  • Although radiotherapy has an established role in the treatment of nonorbital liposarcoma, the role of both radiotherapy and chemotherapy in the management of primary orbital liposarcoma is still unclear.
  • CONCLUSIONS: Orbital liposarcoma remains a diagnostic and surgical challenge.
  • Exenteration remains the treatment of choice, but clinicians must also be aware that liposarcoma may herald the diagnosis of the Li-Fraumeni familial cancer syndrome.
  • [MeSH-major] Liposarcoma / pathology. Neoplasm Recurrence, Local / diagnosis. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Male. Orbit Evisceration. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20022639.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Cassier PA, Dufresne A, El Sayadi H, Pissaloux D, Alberti L, Decouvelaere AV, Ranchere D, Ray-Coquard I, Blay JY: [Targeted therapy of sarcomas]. Bull Cancer; 2008 Oct;95(10):963-74
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Targeted therapy of sarcomas].
  • [Transliterated title] Traitement ciblé des sarcomes.
  • Soft tissue sarcomas can be divided into 6 sub-types based on the underlying molecular biology of the disease:.
  • 1) translocation leading to fusion proteins involving transcription factors or growth factors (Ewing sarcoma, myxoid liposarcoma, dermatofibrosarcoma protuberans);.
  • 3) tumor-suppressor gene deletion (type 1 neurofibromatosis, rhabdoid tumors);.
  • 4) genetic alteration such as amplification of chromosomal regions (well differentiated/dedifferentiated liposarcoma);.
  • Together with the current development of numerous targeted therapies, these recent progress are the basis of tomorrow's personalised medicine for patients with soft tissue sarcoma.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Protein Kinase Inhibitors / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004727.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors
  •  go-up   go-down


73. Marom EM, Goodman PC: Double-ring esophageal sign: pathognomonic for esophageal lipomatosis. J Comput Assist Tomogr; 2002 Jul-Aug;26(4):584-6
MedlinePlus Health Information. consumer health - Esophagus Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The peculiar appearance of the proximal esophagus on CT attributed to esophageal lipomatosis is not well recognized.
  • Its typical CT features should lead to the correct diagnosis and be differentiated from other fatty lesions known to involve the esophagus, namely, lipoma and liposarcoma.
  • [MeSH-major] Esophageal Diseases / radiography. Esophagus / radiography. Lipomatosis / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Administration, Inhalation. Adrenal Cortex Hormones / adverse effects. Adrenal Cortex Hormones / therapeutic use. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pulmonary Disease, Chronic Obstructive / drug therapy. Pulmonary Disease, Chronic Obstructive / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12218824.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


74. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O: Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer; 2007 Jul 1;121(1):199-205
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
  • However, Nutlin-based therapy could be even more important in more common sarcoma types where this aberration is frequent.
  • The well- and de-differentiated liposarcomas have complex marker chromosomes, consistently including multiple copies of the MDM2 locus.
  • Since amplification seems to be a primary aberration in these tumors, whereas amplification in osteosarcoma generally is a progression marker, the underlying biological mechanisms may be different.
  • We have therefore investigated the molecular response to Nutlin treatment in several liposarcoma cell lines with such markers, as well as a panel of other sarcoma cell lines.
  • We report that Nutlin efficiently stabilized p53 and induced downstream p53 dependent transcription and apoptosis in liposarcoma cells with amplified MDM2 in vitro.
  • Thus, Nutlin represents a promising new therapeutic principle for the treatment of an increasing group of sarcomas.
  • [MeSH-major] Imidazoles / pharmacology. Liposarcoma / drug therapy. Liposarcoma / pathology. Piperazines / pharmacology. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Proto-Oncogene Proteins c-mdm2 / metabolism
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Genotype. Humans. Sensitivity and Specificity. Signal Transduction. Tumor Suppressor Protein p53 / metabolism


75. Huang SL, Hsu CL, Yen GC: Growth inhibitory effect of quercetin on SW 872 human liposarcoma cells. Life Sci; 2006 Jun 6;79(2):203-9
Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth inhibitory effect of quercetin on SW 872 human liposarcoma cells.
  • Adipocytic tumors represent the largest single group of soft tissue tumors.
  • In the present study, we investigated the antiproliferative potential of quercetin in SW 872 human liposarcoma cells.
  • Cell viability was significantly influenced by quercetin treatment in a time- and dose-dependent manner.
  • Flow cytometric analyses of SW 872 human liposarcoma cells exposed to quercetin showed that the increase of apoptotic cells was time- and dose-dependent.
  • Quercetin-induced apoptosis in SW 872 human liposarcoma cells was associated with the loss of mitochondrial membrane potential (DeltaPsi(m)).
  • The apoptosis in SW 872 human liposarcoma cells induced by quercetin was mediated through the activation of caspase-3, Bax, and Bak and then cleavage of PARP and downregulation of Bcl-2.
  • These results demonstrate that quercetin may prevent atypical lipomatous tumors/well-differentiated liposarcomas from mature adipocytic proliferation, which may contribute to its antiproliferative function.
  • [MeSH-major] Liposarcoma / drug therapy. Quercetin / pharmacology
  • [MeSH-minor] Annexin A5 / metabolism. Apoptosis / drug effects. Caspase 3. Caspases / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Flow Cytometry. Fluorescein-5-isothiocyanate. Fluorescent Dyes. Humans. Intracellular Signaling Peptides and Proteins / metabolism. L-Lactate Dehydrogenase / metabolism. Membrane Potentials / drug effects. Mitochondria / drug effects. Poly(ADP-ribose) Polymerases / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tetrazolium Salts. Thiazoles. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Liposarcoma.
  • Hazardous Substances Data Bank. QUERCETIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455111.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Fluorescent Dyes; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / bcl-2-Associated X Protein; 298-93-1 / thiazolyl blue; 9IKM0I5T1E / Quercetin; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.1 / GAK protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down






Advertisement